idecabtagene vicleucel

AXP000017.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
TNFRSF17
Originator
bluebird bio
Sponsor
Bristol Myers Squibb

Names

NameTypeSource
idecabtagene vicleucelpreferred name, INNcurator, ncit
Abecmabrandncit
bb2121codencit
ide-celsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
lentivirus
Replication
non replicating
Modifications
replication-incompetent lentiviral vector carrying the anti-BCMA02 CAR; murine extracellular scFv against BCMA, human CD8 alpha hinge and transmembrane domain, CD137 (4-1BB) and CD3 zeta cytoplasmic domains fused in tandem
Transgenes
anti-BCMA chimeric antigen receptor
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C117729
Wikidata
Q106293994
FDA UNII
8PX1X7UG4D

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2021-03-26approvedAbecmaAdults with relapsed or refractory multiple myeloma after two or more prior lines including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibodysource
EMAEU2021-08-18approvedAbecmaAdults with relapsed and refractory multiple myeloma after at least two prior therapies including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, who progressed on the last therapysource
PMDAJP2022-01-20approvedAbecmaRelapsed or refractory multiple myeloma in patients with no prior BCMA-directed CAR T-cell therapy who have had at least three prior lines including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and who progressed after the last of themsource

Clinical trials (19)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06523621Nivolumab in Multiple Myeloma Patients After Idecabtagene VicleucelActive not recruitingPhase 22025-02-282026-03-211Multiple Myeloma
NCT06855121The Norwegian Immunotherapy in Multiple Myeloma StudyRecruiting2025-01-152029-01400AL Amyloidosis; Myeloma Multiple; Plasma Cell Leukemia
NCT06518551ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaRecruitingPhase 12024-11-012029-12-3124Multiple Myeloma; Myeloma; Refractory Multiple Myeloma
NCT06698887A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in KoreaRecruiting2024-09-112031-03-2715Multiple Myeloma
NCT06179888Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaSuspendedPhase 22024-08-272030-03-0184Multiple Myeloma
NCT06048250Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple MyelomaActive not recruitingPhase 12024-04-092027-02-0915Multiple Myeloma
NCT06045806A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell TransplantationActive not recruitingPhase 32023-10-162025-08-1179Multiple Myeloma
NCT06357754Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyRecruiting2023-10-062038-10-0650Chronic Lymphocytic Leukaemia; Multiple Myeloma; Non-Hodgkin Lymphoma
NCT06154902Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene VicleucelActive not recruiting2022-07-292027-07-31350Multiple Myeloma
NCT05393804A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell TransplantActive not recruitingPhase 22022-05-202027-0524Multiple Myeloma
NCT05032820Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple MyelomaCompletedPhase 22022-01-052024-08-2240Multiple Myeloma
NCT04855136Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedPhase 12021-06-012025-04-2521Multiple Myeloma
NCT04196491A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)CompletedPhase 12020-05-272023-06-0713Multiple Myeloma
NCT03651128Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedPhase 32019-04-162026-04-13386Multiple Myeloma
NCT03642626MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive not recruitingPhase 22018-12-182024-02-09150Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
NCT03601078An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple MyelomaCompletedPhase 22018-12-132026-01-15312Multiple Myeloma
NCT03361748Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedPhase 22017-12-132023-12-20149Multiple Myeloma
NCT02658929Study of bb2121 in Multiple MyelomaCompletedPhase 12015-12-222019-07-2267Multiple Myeloma
NCT04771078Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial ReleaseAvailableMultiple Myeloma
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT02786511Longterm Follow-up of Subjects Treated With bb2121Completed2016-04-282019-10-1150Multiple Myelomaname in title: bb2121

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41485914An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression.Internal medicine (Tokyo, Japan)2026name in title: idecabtagene vicleucel
PMID 41627370Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.Advances in therapy2026cited by trial NCT03651128
PMID 41859580Myelodysplastic Syndrome Secondary to Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.Cureus2026name in abstract: idecabtagene vicleucel
PMID 41894689Idecabtagene vicleucel manufacturing and clinical value of out-of-specification products in relapsed and refractory MM.Blood advances2026cited by trial NCT04771078
PMID 41914448Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.American journal of hematology2026name in abstract: idecabtagene vicleucel
PMID 42084945Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.JCI insight2026name in abstract: idecabtagene vicleucel
PMID 42284467Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.Blood cancer discovery2026name in abstract: idecabtagene vicleucel
PMID 42392508Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma.Transplantation and cellular therapy2026name in abstract: idecabtagene vicleucel
PMID 42645380Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.Current oncology (Toronto, Ont.)2026name in abstract: idecabtagene vicleucel
PMID 42747560Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma.Annals of hematology2026name in abstract: idecabtagene vicleucel
PMID 39965175Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025name in title: idecabtagene vicleucel
PMID 40178605Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.Annals of hematology2025name in abstract: idecabtagene vicleucel
PMID 40198886Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.Blood2025cited by trial NCT03361748
PMID 40461939Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.Clinical pharmacokinetics2025name in title: idecabtagene vicleucel
PMID 40514575A successful control of cardiac amyloidosis by idecabtagene vicleucel in a patient with relapsed and refractory multiple myeloma: a case report and literature review.International journal of hematology2025name in title: idecabtagene vicleucel
PMID 40641008Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.Journal of clinical pharmacology2025name in title: idecabtagene vicleucel
PMID 40665490Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma.British journal of haematology2025name in title: idecabtagene vicleucel
PMID 40684380Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis.Hematological oncology2025name in abstract: idecabtagene vicleucel
PMID 40738883Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.Blood cancer journal2025name in abstract: ide-cel
PMID 40749169Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.Blood2025name in abstract: idecabtagene vicleucel
PMID 40875887Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.Blood advances2025name in abstract: idecabtagene vicleucel
PMID 40972962Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.Transplantation and cellular therapy2025name in title: idecabtagene vicleucel
PMID 37855036Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.Haematologica2024name in title: idecabtagene vicleucel
PMID 38263627Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study.British journal of haematology2024name in title: idecabtagene vicleucel
PMID 38423700Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.The Lancet. Haematology2024name in title: idecabtagene vicleucel
PMID 38534054Successful Treatment of Refractory Orbital Plasmacytoma with Chimeric Antigen Receptor T Cell Therapy: A Case Report and Review of the Literature.Ophthalmic plastic and reconstructive surgery2024name in abstract: idecabtagene vicleucel
PMID 38651976Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.Future oncology (London, England)2024cited by trial NCT03651128
PMID 38747092French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.British journal of haematology2024name in title: idecabtagene vicleucel
PMID 38776397Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.Blood advances2024name in abstract: idecabtagene vicleucel
PMID 38834151Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.Transplantation and cellular therapy2024name in title: idecabtagene vicleucel
PMID 38845015Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Journal of hematology & oncology2024name in title: idecabtagene vicleucel
PMID 39042903Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience.Blood advances2024name in title: idecabtagene vicleucel
PMID 39100867Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases.Kidney medicine2024name in abstract: idecabtagene vicleucel
PMID 39197072Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.Blood2024cited by trial NCT03651128
PMID 39379098EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.Journal for immunotherapy of cancer2024name in title: ide-cel
PMID 39588407Local Cytokine Release Syndrome After Idecabtagene Vicleucel Therapy in Patients With Multiple Myeloma: Two Case Reports.Cureus2024name in title: idecabtagene vicleucel
PMID 36690910Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.International journal of hematology2023name in title: idecabtagene vicleucel
PMID 36705644Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.Journal of medical economics2023cited by trial NCT03361748
PMID 36762851Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.The New England journal of medicine2023cited by trial NCT03651128
PMID 36794354Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.CPT: pharmacometrics & systems pharmacology2023cited by trial NCT03361748
PMID 37087950Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.Leukemia research2023cited by trial NCT03361748
PMID 37307173Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.Blood advances2023name in title: idecabtagene vicleucel
PMID 37348705Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation.Transplantation and cellular therapy2023name in title: idecabtagene vicleucel
PMID 37436678Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma.International journal of hematology2023name in abstract: idecabtagene vicleucel
PMID 37558706Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.Blood cancer journal2023name in title: ide-cel
PMID 37592106Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.Nature medicine2023cited by trial NCT02658929
PMID 37597153Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.Advances in therapy2023name in title: idecabtagene vicleucel
PMID 37999117Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.Current oncology (Toronto, Ont.)2023name in abstract: ide-cel
PMID 34933328Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.Blood advances2022cited by trial NCT03361748
PMID 35046063FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research2022cited by trial NCT03361748
PMID 35485211Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.Journal of comparative effectiveness research2022cited by trial NCT03361748
PMID 35939783Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma.Blood advances2022name in title: idecabtagene vicleucel
PMID 33565700Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T.CPT: pharmacometrics & systems pharmacology2021name in abstract: bb2121
PMID 33619368Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.Nature medicine2021cited by trial NCT03361748
PMID 33626253Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.The New England journal of medicine2021name in title: idecabtagene vicleucel
PMID 34145225KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.Blood cancer journal2021name in title: idecabtagene vicleucel
PMID 34256668Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.Current medical research and opinion2021name in title: idecabtagene vicleucel
PMID 34549906From VAD to VRD: Is Transplant Still Needed in the Upfront Setting of Myeloma?Cancer journal (Sudbury, Mass.)2021cited by trial NCT04196491
PMID 31042825Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.The New England journal of medicine2019name in title: bb2121

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39410883Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.Expert opinion on drug safety2026name in abstract: idecabtagene vicleucel
PMID 40966637Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.Blood advances2026name in title: ide-cel
PMID 41284631Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data.Blood2026name in title: idecabtagene vicleucel
PMID 41349540A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma.Cancer cell2026name in abstract: idecabtagene vicleucel
PMID 41391508Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.Transplantation and cellular therapy2026name in abstract: idecabtagene vicleucel
PMID 41396346Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.PharmacoEconomics - open2026name in abstract: idecabtagene vicleucel
PMID 41396414Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma.International journal of hematology2026name in abstract: idecabtagene vicleucel
PMID 414286222025 Update of Cellular Immunotherapy for Plasma Cell Disorders.Turkish journal of haematology : official journal of Turkish Society of Haematology2026name in abstract: ide-cel
PMID 41448297Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.Critical reviews in oncology/hematology2026name in abstract: idecabtagene vicleucel
PMID 41455805CAR T-cells in multiple myeloma: the race to the start line.Bone marrow transplantation2026name in abstract: idecabtagene vicleucel
PMID 41540109CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.Nature medicine2026name in abstract: idecabtagene vicleucel
PMID 41563628Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology2026name in abstract: idecabtagene vicleucel
PMID 41687609The cellular orchestra of CAR T success.Cancer cell2026name in abstract: ide-cel
PMID 41720163Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.Transplantation and cellular therapy2026name in abstract: idecabtagene vicleucel
PMID 41721717Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T-Cell Therapies in Multiple Myeloma.Hematological oncology2026name in abstract: idecabtagene vicleucel
PMID 41744844BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment.Current oncology (Toronto, Ont.)2026name in abstract: idecabtagene vicleucel
PMID 41748023Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes.Transplantation and cellular therapy2026name in abstract: idecabtagene vicleucel
PMID 41777657Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice.Frontiers in oncology2026name in abstract: ide-cel
PMID 41791576Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.Transplantation and cellular therapy2026name in title: idecabtagene vicleucel
PMID 41869788Irreversible parkinsonism after idecabtagene vicleucel: long-term outcome of a rare BCMA CAR T-cell neurotoxicity.Leukemia & lymphoma2026name in title: idecabtagene vicleucel
PMID 41870621Predictors of 30-day readmissions post-CAR-T in patients with relapsed/refractory multiple myeloma using the United States nationwide readmission database.Annals of hematology2026name in abstract: ide-cel
PMID 41886632Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma.Blood advances2026name in abstract: idecabtagene vicleucel
PMID 41899614Real-World Experience with Approved CAR T-Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in 1272 Relapsed/Refractory Multiple Myeloma Patients.Cancers2026name in title: idecabtagene vicleucel
PMID 41951449Infections Post-CAR-T Therapy: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.Clinical therapeutics2026name in abstract: ide-cel
PMID 41974660Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.Blood cancer journal2026name in title: idecabtagene vicleucel
PMID 41975476CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting.Journal of hematology & oncology2026name in abstract: idecabtagene vicleucel
PMID 42086512Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.American journal of hematology2026name in abstract: idecabtagene vicleucel
PMID 42115674Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.Bone marrow transplantation2026name in title: idecabtagene vicleucel
PMID 42128857[Clinical outcomes of idecabtagene vicleucel therapy for relapsed/refractory multiple myeloma: a single-center retrospective analysis].[Rinsho ketsueki] The Japanese journal of clinical hematology2026name in title: idecabtagene vicleucel
PMID 42144192Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma.Transplantation and cellular therapy2026name in abstract: idecabtagene vicleucel
PMID 42169662Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.Hematology/oncology and stem cell therapy2026name in abstract: idecabtagene vicleucel
PMID 42198343Signal Detection and Machine Learning-Based Prediction of Cytokine Release Syndrome in B-Cell Maturation Antigen-Targeting Immunotherapies Using FAERS Data.Pharmaceuticals (Basel, Switzerland)2026name in abstract: idecabtagene vicleucel
PMID 42208766Delay differential equation modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies.Journal of pharmaceutical sciences2026name in title: ide-cel
PMID 42227265Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.British journal of haematology2026name in title: idecabtagene vicleucel
PMID 42257064Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.Case reports in hematology2026name in abstract: idecabtagene vicleucel
PMID 42269145Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Cancer immunology research2026name in abstract: idecabtagene vicleucel
PMID 42275255Product-intrinsic NF-κB-driven transcriptional programs connote durability of CAR-T response in multiple myeloma.Blood2026name in abstract: idecabtagene vicleucel
PMID 42302965Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.Transplantation and cellular therapy2026name in title: idecabtagene vicleucel
PMID 42317206CAR T-cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma.HemaSphere2026name in title: idecabtagene vicleucel
PMID 42345308A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.Current medical research and opinion2026name in abstract: idecabtagene vicleucel
PMID 42364732Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.Transplantation and cellular therapy2026name in title: idecabtagene vicleucel
PMID 42396130Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.HemaSphere2026name in title: idecabtagene vicleucel
PMID 42415719Immune Effector Cell-Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene-Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting.EJHaem2026name in title: idecabtagene vicleucel
PMID 42418682Rapid peak cilta-cel expansion is associated with delayed neurotoxicity in multiple myeloma.Blood2026name in abstract: idecabtagene vicleucel
PMID 42449578Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.Cancers2026name in abstract: idecabtagene vicleucel
PMID 42463487Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.Blood cancer journal2026name in title: idecabtagene vicleucel
PMID 42471153Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2026name in abstract: idecabtagene vicleucel
PMID 42512374Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.Cancers2026name in abstract: idecabtagene vicleucel
PMID 42518303Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.Leukemia & lymphoma2026name in abstract: ide-cel
PMID 42528274Engineering Soluble Recombinant BCMA for Ide-Cel Labeling.European journal of immunology2026name in title: ide-cel
PMID 42542408Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma.Clinical lymphoma, myeloma & leukemia2026name in title: idecabtagene vicleucel
PMID 42618275Diagnostic Tissue Re-Evaluation Supporting the Observation of a 11C-Methionine PET-Negative Residual Paraskeletal Mass in Multiple Myeloma.Internal medicine (Tokyo, Japan)2026name in abstract: idecabtagene vicleucel
PMID 42625595Post-CAR T-cell thyroid dysfunction: destructive thyroiditis identified through thyroid function monitoring in a single-center cohort.Frontiers in oncology2026name in abstract: idecabtagene vicleucel
PMID 42644320Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.British journal of haematology2026name in title: ide-cel
PMID 42657922Parkinsonism-like delayed neurotoxicity after idecabtagene vicleucel therapy for multiple myeloma: clinicopathological, cerebrospinal fluid, and autopsy analyses.Haematologica2026name in title: idecabtagene vicleucel
PMID 42660229Adaptive Bridging and Holding Therapy Frequently Reduces Tumor Burden and Is Associated With Reduced Toxicity After CAR-T Cell Therapy in Multiple Myeloma: A Single-Center Real-World Experience.Transplantation and cellular therapy2026name in abstract: idecabtagene vicleucel
PMID 42705499Delayed Neurologic and Enterocolitis Reporting Patterns for Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in EudraVigilance.Transplantation and cellular therapy2026name in title: idecabtagene vicleucel
PMID 42709039Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.Journal of medical economics2026name in abstract: idecabtagene vicleucel
PMID 42724501Long-term safety and efficacy of BCMA-directed CAR T-cell therapies in multiple myeloma: comparative insights from Cilta-cel, Ide-cel, Anito-cel, and FCARH143.Translational cancer research2026name in title: ide-cel
PMID 42759984Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.Journal for immunotherapy of cancer2026name in abstract: idecabtagene vicleucel
PMID 42844744Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review.Journal of investigative medicine : the official publication of the American Federation for Clinical Research2026name in abstract: idecabtagene vicleucel
PMID 42901918The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program.Nature communications2026name in abstract: idecabtagene vicleucel
PMID 42908664Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database.Frontiers in pharmacology2026name in abstract: Abecma
PMID 42936704Prognostic value of simultaneous [18F]FDG-PET/MRI in refractory multiple myeloma treated with anti-BCMA CAR T.HemaSphere2026name in abstract: idecabtagene vicleucel
PMID 43026080Secondary cancer after CAR-T cell therapy: A French pharmacovigilance analysis.Therapie2026name in abstract: idecabtagene vicleucel
PMID 38718775Toxicity of CAR T-Cell Therapy for Multiple Myeloma.Acta haematologica2025name in abstract: idecabtagene vicleucel
PMID 39373355B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice.The Annals of pharmacotherapy2025name in abstract: idecabtagene vicleucel
PMID 39528086Timeline and outcomes of viral and fungal infections after chimeric antigen receptor T-cell therapy: a large database analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2025name in abstract: idecabtagene vicleucel
PMID 39651553Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma.Expert opinion on biological therapy2025name in title: idecabtagene vicleucel
PMID 39672542Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data.Transplantation and cellular therapy2025name in abstract: idecabtagene vicleucel
PMID 39729503BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.Blood advances2025name in abstract: idecabtagene vicleucel
PMID 39748220Update on B-cell maturation antigen-directed therapies in AL amyloidosis.British journal of haematology2025name in abstract: idecabtagene vicleucel
PMID 39779930T cell malignancies after CAR T cell therapy in the DESCAR-T registry.Nature medicine2025name in abstract: idecabtagene vicleucel
PMID 39786391Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study.Blood advances2025name in title: idecabtagene vicleucel
PMID 39822585Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.HemaSphere2025name in title: idecabtagene vicleucel
PMID 39846935Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome.Cytotherapy2025name in title: idecabtagene vicleucel
PMID 39938011Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.Blood advances2025name in title: idecabtagene vicleucel
PMID 39990276Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.Cancer management and research2025name in abstract: idecabtagene vicleucel
PMID 40053892Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025name in title: idecabtagene vicleucel
PMID 40166474Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients.Frontiers in pharmacology2025name in abstract: idecabtagene vicleucel
PMID 40198765Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.Blood advances2025name in title: idecabtagene vicleucel
PMID 40225701Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma.ClinicoEconomics and outcomes research : CEOR2025name in abstract: idecabtagene vicleucel
PMID 40246942CAR-T for multiple myeloma: practice pearls.Bone marrow transplantation2025name in abstract: idecabtagene vicleucel
PMID 40257295Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma.Transplant infectious disease : an official journal of the Transplantation Society2025name in title: idecabtagene vicleucel
PMID 40330632Prevalence of CCR7-Positive CD8 T Cells as a Prognostic Factor in B-Cell Maturation Antigen -Targeted Chimeric Antigen Receptor T Cell Therapy.EJHaem2025name in abstract: idecabtagene vicleucel
PMID 40346502Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database.BMC cancer2025name in abstract: ide-cel
PMID 40465403FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in title: idecabtagene vicleucel
PMID 40485666Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies.Therapeutic advances in drug safety2025name in abstract: idecabtagene vicleucel
PMID 40504993Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.Blood2025name in abstract: idecabtagene vicleucel
PMID 40534492Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma.Haematologica2025name in abstract: idecabtagene vicleucel
PMID 40546722Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma.Blood neoplasia2025name in abstract: idecabtagene vicleucel
PMID 40610432Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma.Nature communications2025name in title: idecabtagene vicleucel
PMID 40619794Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.Balkan medical journal2025name in abstract: idecabtagene vicleucel
PMID 40626006Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.Frontiers in oncology2025name in abstract: idecabtagene vicleucel
PMID 40638198Real-world data provide a CARbon copy for ide-cel.Blood2025name in title: ide-cel
PMID 40644619Sequential BCMA CAR T-cell therapy in refractory multiple myeloma.Blood advances2025name in abstract: idecabtagene vicleucel
PMID 40671605Chimeric antigen receptor T-cell therapy for multiple myeloma.Current opinion in oncology2025name in abstract: idecabtagene vicleucel
PMID 40672475Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.medRxiv : the preprint server for health sciences2025name in title: ide-cel
PMID 40674751Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?Blood advances2025name in title: ide-cel
PMID 40680848Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma.Transplantation and cellular therapy2025name in abstract: idecabtagene vicleucel

NIH grants

ProjectTitleOrganisationPIYearsLinked by
ZIABC011439Development of Chimeric Antigen Receptors Targeting Multiple MyelomaDIVISION OF BASIC SCIENCES - NCIKOCHENDERFER, JAMES2024–2024name in abstract: idecabtagene vicleucel
U01AI113362Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE)UNIVERSITY OF CALIFORNIA, SAN FRANCISCOVINCENTI, FLAVIO2021–2023name in abstract: ide-cel
U01FD007937Development of novel methods to enable robust comparison of real-world Progression Free Survival (rwPFS) and Clinical Trial PFS in Multiple MyelomaJANSSEN RESEARCH & DEVELOPMENT, LLCSARSOUR, KHALED2023–2023name in abstract: Abecma

Notes

Anti-BCMA 4-1BB CAR; co-developed by bluebird bio (later 2seventy bio) and Celgene/BMS.

How to cite

idecabtagene vicleucel (AXP000017.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000017.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.